Rakovina Therapeutics Inc. (TSXV:RKV) - Executive Chairman- Jeffrey Bacha.
Executive Chairman
Source: CEO Clips
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Rakovina Therapeutics Inc. (RKV) is advancing its programs for malignant tumour treatment therapies
  • The Canadian company is developing medicines that target and kill cancer cells
  • It has three programs undergoing trials, hoping one will be approved for cancer treatment
  • The programs have been designed to solve a tumour’s developed resistance to therapy
  • It is now optimizing the programs and choosing the suitable molecule to target and advance for human clinical trials
  • Rakovina Therapeutics Inc. (RKV) is down 29.41 per cent and is trading at $0.12 per share as of 4:00 p.m. ET

Rakovina Therapeutics (RKV) is advancing its programs for malignant tumour treatment therapies.

The Canadian biotechnology company is developing medicines that target and kill cancer cells and advance innovative cancer treatments with the potential to improve patient outcomes across multiple tumour types.

“[regarding the programs] when we’re treating a tumour, eventually the tumour will stop responding to that treatment and become resistant,” Rakovina’s Executive Chairman, Jeffrey Bacha, said.

It has three different programs to fight off dangerous tumours, its kt 2000 Next Generation PARP-inhibitors, kt-3000 Dual Action DDR-inhibitors, and its kt-4000 DNA Damaging DDR-inhibitors. It is hoping at least one of these will make it to market to treat cancer.

According to Rakovina, the programs have been designed to solve a tumour’s developed resistance to therapy and allow it to begin reacting to treatment again. All the programs are still in pre-clinical trials.

“But we have a program… by impacting into a secondary pathway that seems to overcome the resistance of treatment,” Bacha said.

The company stated it has proof-of-concept for this theory and is now moving on to optimizing the programs and choosing a suitable molecule to target and advance for human clinical trials.

Rakovina Therapeutics Inc. (RKV) is down 29.41 per cent and is trading at $0.12 per share as of 4:00 p.m. ET.

More From The Market Herald

" Satellos Bioscience (TSXV:MSCL) changing the way we think of degenerative muscle diseases

Satellos Bioscience (MSCL) has filed a patent application with the US Patent and Trademark Office.

" NervGen Pharma (TSXV:NGEN) announces US$15M private placement

NervGen Pharma (NGEN) has announced a non-brokered private placement for gross proceeds of US$15,225,000.

" Feeding our plant-based future

One of the fastest-growing segments today is the plant-based industry, as the push towards cleaner lifestyles, eating habits, and sustainable living choices fuel

" Salona Global (TSXV:SGMD) expands product distribution

Salona Global (SGMD) has signed an agreement to distribute the Hyperice suite of products and delivered 600 units of its newly launched Mio-Guard.